×
SPIDS Week 2024, 11-09-2024

Updates in the Treatment of AmpC-Producing Enterobacterales

Classical Presentation

  • Objectives:
    • This presentation will cover the following:
      • Understanding the mechanism of AmpC-mediated resistance
      • Discussing the previous management of AmpC-producing Enterobacterales
      • Presenting the updates in the management of AmpC-producing Enterobacterales (including IDSA updated guidelines)
      • The novel antibiotic and combination therapy options



Current Treatment Approach for CRAB

Classical Presentation

Objectives:

This presentation will cover the following:

Understanding the mechanism of resistance and the threat of CRAB

Identifying genotypes that underlie resistant phenotypes

Discussing the traditional management of Acinetobacter spp.

The clinical challenges of CRAB treatment

The characteristics and roles of new agents

Proposed treatment strategies for CRAB



Therapeutic Drug Monitoring (TDM): An Underestimated Powerful Tool

Classical Presentation

Objectives:

Clear the ambiguity around “Therapeutic Drug Monitoring”! This presentation will cover the following key points:

Understanding TDM and the importance of dose optimization

Understanding different related terminology (e.g., trough, peak, area under the curve), their indications, and relevance

Understanding the basis of dosing, intervals, and special administration methods (e.g., extended infusion time)

The crucial role and utility of TDM in the treatment of infectious diseases

Practical and novel approaches to therapeutic drug monitoring and antibiotic dosing



Staying Ahead of Infectious Diseases: Pipelines Corner

(Co-organized with the Saudi Society of Clinical Pharmacy) Presentation and Open Discussion

Objectives:

This session will introduce you to the recently approved and soon-to-be-approved antimicrobials. It will keep you one step away from using the novel antibiotics, antifungals, and antivirals. It additionally covers issues related to their use, spectra, indications, and limitations. Look no further; join the antimicrobial pipeline session!



SPIDS Plenary: Ventilator-Associated Pneumonia: Connecting the Dots

Open Discussion (Forum)

Objectives:

A general and thorough review of ventilator-associated pneumonia that touches on:

The current definition of VAP in pediatrics

Diagnosis-related issues such as the challenges of establishing an accurate VAP diagnosis, sampling (the role of mini-BAL), the performance/positive predictive values of different diagnostic parameters (e.g., respiratory symptoms, ventilatory parameters, radiological findings, etc.)

Therapeutic-related issues (e.g., the role of combination therapy, empiric use of anti-staphylococcal and anti-pseudomonal agents, the impact of the recent CLSI breakpoint changes on the empiric and definitive use of aminoglycosides, the duration of therapy, the role of inhaled antimicrobials)

The impact of MRSA screening on treatment



Empiric Antibiotics in the NICU: Is It Still Aminoglycosides?

Classical Presentation

Objectives:

Are we moving away from our long-standing practice for neonatal sepsis, or are we still holding tight to ampicillin and gentamicin? Define your future practice after this eye-opening presentation, which includes:

A brief overview of the current practice (ampicillin/aminoglycoside) for neonatal sepsis, the origin behind this recommendation, rationales, and the validity of this recommendation in the present time

The indications/scenarios where deviation from this practice is recommended and the appropriate alternatives

The impact of the new CLSI and EUCAST aminoglycoside breakpoints on these recommendations

Challenges and limitations



Understanding Culture-Negative Sepsis

Classical Presentation

Objectives:

Do you believe in “culture-negative sepsis”? This presentation will answer this question and many others:

What is culture-negative sepsis in newborns?

Are we diagnosing culture-negative sepsis? What are the criteria for culture-negative sepsis?

The role of common laboratory biomarkers and diagnostic imaging

When to treat culture-negative sepsis?

How culture-negative sepsis compares to culture-positive sepsis (morbidity and mortality)

Management considerations (e.g., the role of de-escalation, duration, etc.)



Perinatal HIV: The Current Approach for Prevention

Classical Presentation

Objectives:

This presentation will cover the following issues:

Epidemiology of perinatal HIV infection

Risk factors that lead to increased perinatal HIV transmission (regionally)

Preventive measures needed to prevent perinatal HIV transmission to children

Highlights on the recent changes in the recommendations for the prevention of perinatal HIV transmission, including the local recommendations



Imaging Approaches for Patients with Fever of Unknown Origin

Classical Presentation

Pending